Taiho Oncology, Inc.
Joseph Vu currently serves as the Executive Director of Regulatory Affairs Strategy & CMC at Taiho Oncology, Inc. since January 2024. Prior experience includes serving as Executive Director of Regulatory Affairs - CMC at Astex Pharmaceuticals, Inc. from April 2018 to December 2023, and as Director of Regulatory Affairs - CMC at Acerta Pharma B.V. from April 2016 to April 2018. Joseph has held positions such as Associate Director of Regulatory Affairs - CMC at Pharmacyclics, an AbbVie Company, and Sr. Manager, Global Regulatory Lead at Baxter Healthcare. Joseph began career at Baxter Healthcare and progressed through various roles, including Specialist in Quality & Regulatory Compliance at Amgen and Senior Analyst at One Lambda, Inc. Educational achievements include a Master of Science in Biochemistry from UCLA, a Juris Doctor from Southwestern Law School, and dual Bachelor’s degrees in Chemistry and Molecular Biology from the University of California, Santa Cruz.
This person is not in any teams
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com